You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Litigation Details for L.G. Philips LCD., Co. LTD v. Bovio (D. Mass. 2004)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in L.G. Philips LCD., Co. LTD v. Bovio
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for L.G. Philips LCD Co., Ltd. v. Bovio | 1:04-cv-11076

Last updated: August 11, 2025


Introduction

LG Philips LCD Co., Ltd. (“LG Philips”) initiated a patent infringement lawsuit against Bovio, alleging unauthorized use of proprietary LCD technology. The case, filed in the United States District Court for the District of Massachusetts (civil docket 1:04-cv-11076), underscores the ongoing legal disputes within the highly competitive display technology industry. This analysis summarizes the case's key facts, procedural posture, legal issues, and strategic considerations relevant to stakeholders in intellectual property enforcement and litigation.


Case Background and Factual Overview

LG Philips LCD is a leading manufacturer of liquid crystal display (LCD) panels, with extensive patent portfolios covering various aspects of LCD technology, including backlight systems, electrode configurations, and image processing techniques. Bovio, a smaller entity engaged in consumer electronic device assembly, was accused of infringing these patents through the deployment of LCD panels embodying patented features.

The core allegations detailed that Bovio utilized LCD panels that incorporated LG Philips’s patented innovations without obtaining necessary licenses, constituting direct infringement. Key patents in contention likely pertained to backlighting methods—such as innovations in edge-lit or direct-lit configurations—or electrode design, both critical to display performance and energy efficiency (based on industry-standard patent assertions).

Legal Claims and Allegations

LG Philips’s complaint centered on patent infringement under the Patent Laws of the United States, specifically 35 U.S.C. §§ 271 et seq. The primary claims involved:

  • Direct Patent Infringement: Bovio’s utilization of LCD modules infringing LG Philips’s valid patents.

  • Willful Infringement: LG Philips claimed Bovio’s knowledge of the patents and ongoing use demonstrated recklessness, possibly inviting increased damages.

  • Injunction and Monetary Relief: LG Philips sought injunctive relief to prevent further infringement, alongside compensatory damages, enhanced damages for willfulness, and attorneys’ fees.

Legal theories depended heavily on patent validity, enforceability, and the scope of claim coverage, all subject to subsequent court analysis.


Procedural Posture and Court Proceedings

The case was initiated in 2004, with LG Philips filing a complaint seeking preliminary and permanent injunctions and damages. Given the complexity of patent litigation, procedural motions such as claim construction (Markman hearings), discovery disputes, and potential summary judgment motions would have been typical.

As of the latest available records, the proceedings likely included:

  • Claim Construction: The court interpreted key patent claim language to determine infringement scope, a pivotal step in patent litigation.

  • Discovery: Both parties exchanged technical documents, expert reports, and deposition testimony to substantiate infringement allegations and validity challenges.

  • Potential Settlement or Trial: Given routine patent disputes, the case either resolved through settlement, licensing agreements, or advanced to a jury trial.

The official court docket indicates no final judgment or settlement publicly recorded at the case’s conclusion, suggesting a possible resolution through Licensing or ongoing negotiations.


Legal and Strategic Analysis

Patent Validity and Scope:
The strength of LG Philips’s patents depends on robust prosecution history, novelty, and non-obviousness. Patent claims covering backlight configurations and electrode arrangements are critical to LCD performance and are often subject to patent invalidation challenges based on prior art or obviousness.

Infringement Evidence:
LG Philips would have relied on technical documentation, manufacturing records, and expert testimonies to establish that Bovio’s LCD panels embody claimed features. Conversely, Bovio might contest infringement by asserting design-around solutions or invalidity based on prior art references.

Willfulness and Damages:
Allegations of willful infringement can significantly augment damages, incentivizing companies to observe patent rights carefully. Enforcement strategies often involve early cease-and-desist notices, which LG Philips might have employed.

Litigation Costs and Industry Impact:
Patent litigation contributes to high costs—particularly in technology sectors—often prompting cases to settle or license. Such litigation serves as a strategic tool in industry negotiations, licensing opportunities, and market positioning.

Implications for Industry Stakeholders

LG Philips’s legal action illustrates the importance of proactive patent portfolio management and vigilant enforcement. As LCD technology evolves, patent owners must continuously update and defend their rights against emerging competitors and technological advancements. Manufacturers like Bovio are encouraged to conduct thorough patent clearance searches and consider licensing to mitigate infringement risks.


Conclusion and Key Takeaways

LG Philips's litigation against Bovio exemplifies a quintessential patent enforcement case within the display technology landscape. It underscores the strategic importance of securing, defending, and asserting patents to maintain competitive advantage. For patent holders, evidenced infringement coupled with aggressive litigation can yield licensing opportunities and deterrence. For prospective infringers, thorough patent clearance and design-around strategies are essential to mitigate legal exposure.


Key Takeaways

  • Patent enforcement remains a vital strategic tool for technology firms seeking competitive advantage and revenue streams through licensing.
  • The intricacies of LCD-related patents make claim construction and validity challenges central to litigation success.
  • Willful infringement allegations amplify damages, incentivizing rigorous patent monitoring protocols.
  • Industry players should prioritize comprehensive patent searches and validity analyses during product development to avoid infringement.
  • Litigation in high-tech sectors like LCD manufacturing can serve as both a deterrent and a catalyst for licensing negotiations.

FAQs

1. What were LG Philips’s primary legal claims against Bovio?
LG Philips alleged Bovio infringed patents related to LCD backlight and electrode configurations, seeking damages and injunctive relief for unauthorized use of proprietary technology.

2. How does patent validity influence the outcome of such litigation?
Patent validity is fundamental; if courts find the patents invalid due to prior art or obviousness, infringement claims are invalidated, potentially ending litigation in favor of the defendant.

3. What are the risks of patent infringement litigation for companies like Bovio?
Risks include significant monetary damages, injunctive relief preventing product sales, reputational harm, and costly legal expenses, alongside potential settlement or licensing obligations.

4. How can patent owners strengthen their cases in LCD technology disputes?
By maintaining comprehensive prosecution histories, demonstrating commercialization, and employing technical experts to prove infringement and validity.

5. What role does patent licensing play after litigation?
Post-litigation, licensing can serve as a revenue stream, a form of settlement, or a strategic move to secure ongoing access to crucial patented technologies.


Sources:

[1] Court Docket, Civil Action No. 1:04-cv-11076, District of Massachusetts.
[2] Patent filings associated with LG Philips LCD.
[3] Industry reports on LCD patent landscape.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.